Moleculin Biotech, Inc. (MBRX)

NASDAQ: MBRX · IEX Real-Time Price · USD
5.91
+0.37 (6.68%)
At close: Mar 28, 2024, 4:00 PM
5.83
-0.08 (-1.35%)
After-hours: Mar 28, 2024, 7:49 PM EDT
6.68%
Market Cap 13.41M
Revenue (ttm) n/a
Net Income (ttm) -29.77M
Shares Out 2.23M
EPS (ttm) -15.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,209
Open 5.58
Previous Close 5.54
Day's Range 5.18 - 6.24
52-Week Range 4.34 - 24.75
Beta 1.98
Analysts Strong Buy
Price Target 101.67 (+1,620.31%)
Earnings Date Mar 22, 2024

About MBRX

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 2, 2016
Employees 15
Stock Exchange NASDAQ
Ticker Symbol MBRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for MBRX stock is "Strong Buy." The 12-month stock price forecast is $101.67, which is an increase of 1,620.31% from the latest price.

Price Target
$101.67
(1,620.31% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference

Live webcast on Thursday, April 4 th at 4:10 PM ET HOUSTON, March 28, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company ...

10 hours ago - PRNewsWire

Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity

Live webcast with Walter Klemp, Chairman and Chief Executive Officer, on Thursday, March 28 th at 12:00 PM ET HOUSTON , March 27, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Molecul...

1 day ago - PRNewsWire

Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML

Patent, once issued, will provide composition of matter protection through 2040, with potential for additional term extension Next-generation anthracycline uses unique lipid-based delivery technology ...

1 day ago - PRNewsWire

Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

–     Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 60% (50% CR) in 2nd line AML subjects –     AnnAraC has potential to fill significant unmet need and expected to increase ...

3 days ago - PRNewsWire

Moleculin Reports Full Year 2023 Financial Results

–    Year marked by growing body of positive Annamycin efficacy and safety clinical data expected to support advancement into a pivotal study for AML –   Company to host conference call and webcast Mo...

6 days ago - PRNewsWire

Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast

In-depth discussion of stratification of Company's 2nd line data of Annamycin as a therapy for acute myeloid leukemia (AML) Guidance to be provided for clinical development strategy for advancement of...

8 days ago - PRNewsWire

Moleculin Announces Reverse Stock Split

HOUSTON , March 19, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clin...

9 days ago - PRNewsWire

Moleculin to Present at the 36th Annual ROTH Conference

Live webcast fireside chat on Monday, March 18 th at 9:00 AM PT HOUSTON , March 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceu...

16 days ago - PRNewsWire

Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

– MB-106 AML Phase 1B/2 trial (MB-106) preliminary data readout: Reached 67% recruitment – MB-106 preliminary results: Intent to Treat CR rate of 40% plus a CR/ CRi rate of 47% (N=15); Dosed Per Proto...

2 months ago - PRNewsWire

Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market

HOUSTON , Dec. 20, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. (NASDAQ: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h...

3 months ago - PRNewsWire

Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting

- CR rate of 36% in Intent to Treat or ITT (n=11) subjects with durability - CR rate of 44% in subjects treated with Annamycin (n=9) - Durability of CR's up to 8 months & climbing (no relapses to date...

3 months ago - PRNewsWire

Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months

–        MB-106: CR rate of 38% (N=8) with durability up to 8 months –        Builds on CRi rate of 60% in MB-105 monotherapy AML trial last cohort (N=5) –        MB-107: Phase 1B median extended over...

4 months ago - PRNewsWire

Moleculin Reports Third Quarter 2023 Financial Results

– Ends Quarter with $24.6 million in Cash with Runway Estimated into Third Quarter of 2024 – Third quarter marked by additional positive clinical data from Annamycin lead development programs – Growin...

4 months ago - PRNewsWire

Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast

HOUSTON , Nov. 7, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinic...

5 months ago - PRNewsWire

Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases

– Poster Presented at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting – Annamycin continues to be 100% non-cardiotoxic – Annamycin has Fast Track Status and Orphan Drug Designation f...

5 months ago - PRNewsWire

Moleculin to Participate in the Virtual Investor Ask the CEO Conference

Live video webcast with Walter Klemp, CEO and Jonathan Foster, Executive VP and CFO of Moleculin on Tuesday, October 25 th at 12:00 PM ET HOUSTON , Oct. 11, 2023 /PRNewswire/ -- Moleculin Biotech, Inc...

6 months ago - PRNewsWire

Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

– Phase 1B portion of Phase 1B/2 study demonstrated preliminary CR/CRi rate of 33% (n=6) – Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of AML HOUSTON , Oct. ...

6 months ago - PRNewsWire

Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)

– Data readouts expected before year end – Previously reported preliminary efficacy data on its Phase 1B/2 clinical trial with Annamycin in monotherapy treatment of STS lung mets with >60% of the subj...

6 months ago - PRNewsWire

Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

– Annamycin continues to demonstrate no evidence of cardiotoxicity to date, now in a total of 62 subjects across three of the Company's Annamycin clinical trials – Next generation anthracycline, Annam...

6 months ago - PRNewsWire

Moleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

HOUSTON , Sept. 14, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clin...

7 months ago - PRNewsWire

Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference

HOUSTON , Sept. 5, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clini...

7 months ago - PRNewsWire

Moleculin Reports Second Quarter 2023 Financial Results

– Ongoing progress across ongoing clinical development programs with growing body of positive preclinical and clinical data – Released Clinical Trial Update press release yesterday providing the quart...

8 months ago - PRNewsWire

Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones

– Announces successful completion of the Phase 1B portion of its Phase 1B/2 clinical trial Annamycin in combination with Cytarabine for the treatment of AML (MB-106) and opens the Phase 2 portion for ...

8 months ago - PRNewsWire

Moleculin Retains Shareholder Intelligence Services, LLC to Investigate Potential Naked Short Selling

HOUSTON , Aug. 7, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting ...

8 months ago - PRNewsWire

Moleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and Webcast

HOUSTON , Aug. 3, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti...

8 months ago - PRNewsWire